Videos

Drs John Mascarenhas and Ruben Mesa review unmet needs and challenges in treating myelofibrosis.

Second-line treatment approaches available for metastatic urothelial carcinoma and considerations for switching therapies vs re-challenging with prior therapy.

What to know regarding molecular testing assays used to assess patients with metastatic urothelial carcinoma.

Ruben Mesa, MD, and John Mascarenhas, MD, review the patient selection of extended molecular panels and the appropriate interval for molecular profiling for the management of myelofibrosis.

Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.

Ghasson K. Abou-Alfa, MD, discusses that phase 2 study of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma.

Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.

Loretta Nastoupil, MD, and John Burke, MD, discuss the future of the therapeutic landscape for patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.

Experts discuss the LOTIS-2 trial that studied loncastuximab tesirine, a CD19-targeted monoclonal antibody for treating patients with relapsed/refractory diffuse large B-cell lymphoma.

A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, discuss the recent identification of EGFR exon 20 insertion+ mNSCLC and how patients responded before the new drugs were introduced.

Scott Kopetz, MD, PhD, FACP, explains the purpose of the phase 1b KISIMA-01 study of the ATP128 vaccine used with or without with or without ezabenlimab to treat patients with advanced colorectal cancer.

Tycel Jovelle Phillips, MD, discusses the safety and efficacy of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma

Othman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.

Sattva S. Neelapu, MD, discusses the challenges surrounding chimeric antigen receptor T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

Shaakir Hasan, DO, discusses the disparities identified in the bladder cancer space through a real-world prospective study.

Guiseppe Curigliano, MD, discusses the design and results of the HER2CLIMB-02 study which evaluated the efficacy of tucatinib in combination with trastuzumab and capecitabine in HER2-positive breast cancer patients with and without brain metastases compared to placebo.

First-line treatment options available for patients with metastatic urothelial carcinoma and variables that impact treatment selection.

Considerations for incorporating adjuvant nivolumab into treatment plans for appropriate patients with advanced urothelial carcinoma based on early, recently presented data.

Experts in hematology-oncology share factors to consider when approaching the treatment of myelofibrosis.

Cathy Eng, MD, FACO, FASCO, discusses how biomarkers are being explored to aid the treatment of anal cancers.

Peter Martin, MD, explains the importance of reviewing real-world databases and the results of a real-world study of treatment patterns and outcomes of patients with mantle cell lymphoma.

Rodney P. Rocconi, MD, discusses a subgroup analysis of the phase 2b VITAL study in which the efficacy of maintenance Vigil immunotherapy is explored in patients with newly diagnose advanced ovarian cancer who are homologous recombination proficient.

Experts discuss tafasitamab, a CD19-targeted monoclonal antibody (mAb) for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Loretta Nastoupil, MD, and John Burke, MD, review data from the L-MIND study presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

An overview of CD19 as a treatment target for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Insight into the combination of tafasitamab plus lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Stephanie Lee, MD, MPH, discusses the study of ruxolitinib plus best available therapy as a second-line treatment for patients with chronic graft-versus-host disease.

Bijal Shah, MD, MS, discusses the results of treatment with the chimeric antigen receptor T-cell therapy brexucabtagne autoleucel in the ZUMA-3 trial in patients with acute lymphoblastic leukemia.